DigestRedComo funciona
Red
/
Empresas
Id
No verificado

Idorsia Pharmaceuticals Ltd

Sobre qué escribimos

Anuncios brevesFarmacéutica

71 Comunicados de prensa

Ver todos los comunicados de prensa
27/04/2026
Farmacéutica
Anuncios breves
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmacéutica
Anuncios breves
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
08/04/2026
Farmacéutica
Anuncios breves
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
29/03/2026
Farmacéutica
Anuncios breves
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
23/03/2026
Farmacéutica
Anuncios breves
Idorsia announces the nomination of three candidates for election to the Board of Directors
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
15/03/2026
Farmacéutica
Anuncios breves
Idorsia announces management change
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/03/2026
Farmacéutica
Anuncios breves
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmacéutica
Anuncios breves
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
12/02/2026
Farmacéutica
Anuncios breves
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0
05/02/2026
Farmacéutica
Anuncios breves
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Fuente
Idorsia Pharmaceuticals Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0